Elizabeth AllenResearch Associate II, Frontier Science Yanjie (Belle) BaoScientist II, Formulation Development James BarlowDirector of the Board
James Barlow is a member of the Board of Directors of North American Health Care, Inc., a privately held company that provides contractual services to facilities specializing in post-acute care, subacute care, short and long-term rehabilitation, and skilled nursing in the United States. Mr. Barlow is a C-level financial executive with more than30 years of experience leading teams in the successful strategic achievement of financial and operational goals, and expertise in domestic and international operations (5 continents, 23 countries), financial planning, forecasting and reporting, restructurings, business development and integrations, treasury and investor relations. As an Executive Officer (Principal Accounting Officer) at Allergan, Inc. (NYSE:AGN), he oversaw financial due diligence, integration and structuring for more than 100 asset purchases, sales, business combinations and licensing transactions, the spin-off of Advanced Medical Optics, the $3.3 billion acquisition of Inamed and more than $4.5billion in other transactions. He ensured consistent application of all corporate policies and procedures and alignment with global reporting and corporate compliance requirements, made recommendations globally to improve financial operations and participated in robust financial planning/forecasting activities.
Hari BhaskaranScientist I, Transnational Biology Jonathan BushResearch Associate I, Formulation Development Arisa Iga CaleResearch Associate I, RNA Production Giulio CattarossiSenior Research Associate, Translational Biology Lena CeballosSenior Research Associate, Analytical Development Hanyi (Han) ChangResearch Associate I, Formulation Development Brandon ChenIntern, Investor Relations Pad ChivukulaCSO, COO
Pad Chivukula, Ph.D., is the Chief Scientific Officer and Chief Operating Officer of Arcturus Therapeutics. Dr. Chivukula has an exceptional and technically solid foundation in nanoparticle technology. Prior to Arcturus, from 2008 until February 2013, Dr. Chivukula was employed by Nitto, where his titles included Group Leader and Chief Scientist. Dr. Chivukula brings over 15 years of experience in drug delivery and therapeutic drug development, including leading the polymeric RNAi research department at Nitto. Dr. Chivukula has a Ph.D. in Pharmaceutical Chemistry from the University of Utah where he specialized in nanoparticle technology.
ThanhChau DamResearch Associate II, Translational Biology Jared DavisDirector, RNA Process Development Peter FarrellChairman of the Board
Dr. Peter Farrell is the founder, former long-term CEO and current Chairman of ResMed (NYSE:RMD). Farrell has been Chairman and a director of ResMed since 1989, when the company began as a management buyout of sleep technology from Baxter Healthcare. Peter was previously Foundation Director of the University of New South Wales (UNSW) Graduate School for Biomedical Engineering (1978-89) while simultaneously serving as Vice President of Research & Development for Baxter Healthcare in Tokyo (1984-89). He is also on the board of trustees of The Scripps Research Institute in La Jolla and is Chairman of the Boston-based POC NMR diagnostic company, WaveGuide. Dr. Farrell is a fellow or honorary fellow of several professional bodies, including the US National Academy of Engineering. He was inducted as 1998 San Diego Entrepreneur of the Year for Health Sciences, 2001 Australian Entrepreneur of the Year and 2005 US National Entrepreneur of the Year for Health Sciences. In 1998, Peter joined the Sleep Medicine Executive Council at Harvard Medical School, served as vice chairman from 2000 to 2010 and then as chairman from 2010 until 2013. He is on various academic advisory boards including UCSD's Jacobs School of Engineering, where he was named the 2012 Gordon Fellow, UCSD's Rady Business School and the MIT Dean of Engineering's Advisory Council. Peter holds a B.E. with honors in chemical engineering from the University of Sydney, an SM in chemical engineering from MIT, a PhD in bioengineering from the University of Washington, Seattle, and a DSc from UNSW for research which resulted in improved treatment for both hemodialysis and peritoneal dialysis patients.
Nancy FuselliDirector, Quality & Regulatory Affairs Sina GhaffarnejadIntern, Drug Discovery Jose GonzalesResearch Associate II, Translational Biology JP HeadleyAssociate Director, Accounting and Operations Michael HodgesR&D & Medical Consultant Alice HouSenior Research Associate, Analytical Development Daniel HwangSenior Accountant Priya KarmaliSenior Director, Pharmaceutical Development
Priya Karmali is Senior Director of Pharmaceutical Development at Arcturus Therapeutics Ltd. Dr. Karmali joined Arcturus in 2015 and is responsible for research and development efforts for LUNAR™ technology, Arcturus’ lipid mediated nucleic acid delivery system. She has over 15 years of experience in the field of lipid-based drug delivery systems from discovery to development. Prior to Arcturus, Priya was Associate Director of Formulation Development at Regulus Therapeutics where she led drug product development efforts for miRNA therapeutic drugs currently in various stages of clinical trials. Prior to joining Regulus, Priya was a Principal Scientist at Nitto Denko where she led formulation development efforts for their Vitamin A targeted siRNA lipid nanoparticle for treatment of liver fibrosis. Dr. Karmali has a Ph.D. in Chemistry from the Indian Institute of Chemical Technology where she specialized in development of novel liposomal nucleic acid delivery systems for use in non-viral gene therapy and DNA vaccination. She is an author or inventor on over 35 scientific publications and patents.
Jae Heon (Jay) KimIntern, Formulation Development Inna KoukharevaSenior Manager, Analytical Development Kristen KuakiniResearch Associate I, RNA Sciences KC KummerfeldSenior Director, Finance & Corporate Controller Yi KuoResearch Associate I, RNA Production Thu LeIntern, Formulation Development Allison LeeIntern, Formulation Development Jessica MendezAssociate Director, Human Resources Robin LeeSenior Research Associate, Formulation Development Samuel LeeResearch Associate I, RNA Process Development Sharon LeeResearch Associate I, Frontier Science Angel LeuSenior Research Associate, Frontier Science Jilong LiScientist, Formulation Development Pattraranee (Patty) LimphongSenior Manager, RNA Process Development Steven LyResearch Associate I, Analytical Development Maher AlayyoubiScientist II, RNA Process Development Dr. Magda MarquetDirector of the Board
Dr. Magda Marquet is the co-founder and co-CEO of Alma Life Sciences, an investment and consulting firm with a portfolio of over twenty companies in the areas of diagnostics, digital health and pharmaceuticals, Chairman and co-Founder of Althea, an Ajinomoto company, and Co-founder of AltheaDx, a precision medicine company. She has three decades of experience in the biotechnology industry in the US and Europe. Prior to starting Althea, Dr. Marquet held management positions at Vical Inc., Amylin Pharmaceuticals, Protein Polymer Technologies, Syntro Corporation and Transgene. She currently serves as a Board member for Sente, Independa and Portable Genomics. She is also co-Chairman of the Advisory Board of MD Revolution. Dr. Marquet was Chairman of BIOCOM (2013-2014) and is Chair of the Board of Visitors of the UCSD Moores Cancer Center. She serves as a Director of the Economic Development Corporation (EDC- Executive Committee) and of the Kyoto Symposium Organization. She is also a member of the UCSD Biological Sciences Dean Leadership Council and an advisor for the Chopra Foundation. Dr. Marquet holds a Ph.D in Biochemical Engineering from INSA/University of Toulouse, France. Dr. Marquet has received numerous awards throughout her career including the 2005 Regional Ernst&Young Entrepreneur of the Year Award in the Life Sciences category, the Athena Pinnacle Award and the Exemplary Service Award from the San Diego Business Journal. She is the first woman inducted in the Connect Entrepreneur Hall of Fame (2016) and the Director of the Year Award recipient (2016-Corporate Governance) from the Corporate Directors Forum.
Daiki MatsudaSenior Scientist, Frontier Science Mike MatsumotoResearch Associate I, Drug Discovery Kim McAdenPurchasing Manager Rajesh MukthavaramScientist I, Formulation Development Michelle NguyenResearch Associate I, Analytical Development Jocelyn OngFront Desk Coordinator/Administrative Assistant I Jenny ParkScientist, RNA Sciences Suezanne ParkerVice President, Translational Biology Paula PattersonResearch Associate II, Frontier Science Joseph E. PaynePresident & CEO, Director of the Board
Joseph E. Payne, is the President and Chief Executive Officer of Arcturus Therapeutics Ltd. He serves on Arcturus’s Board since March 2013. He brings with him an exceptional track record of ushering novel therapeutics to the clinic including targeted RNA medicines utilizing lipid-mediated delivery technologies. Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto as evidenced by over 40 publications and patents, and several investigational new drug (IND) clinical candidates. His academic training includes a Bachelor's Degree in Chemistry, magna cum laude from Brigham Young University, a Master of Science in Synthetic Organic Chemistry from the University of Calgary and Executive Training Certification from MIT Sloan School of Management.
Carlos Perez-GarciaSenior Scientist, Translational Biology Natalie PrigozhinaAssociate Director, Drug Discovery Kumar RajappanPrincipal Scientist, Chemistry Janet ReedExecutive Assistant Neda SafarzadehDirector, Investor Relations/Public Relations/Marketing Joseph RobertsManager, Technical and Revenue Accounting Scott RobertsSenior Manager, CMC Marciano SabladSenior Manager, Translational Biology Hazel SantosAccounts Payable Specialist Andrew SassineDirector of the Board
Andrew Sassine served on the Board of Directors of ICAD Inc. for two years. Mr. Sassine also serves on the board of directors of Nasdaq listed Gemphire Therapeutics, Inc.(GEMP), an early-stage cardiovascular drug company formed by a licensing agreement with Pfizer Inc. He also is Chairman of the Board of privately held ComHear Inc., a digital audio software and device company. Mr. Sassine previously served on the board of Acorn Energy, Inc, CNS Response, Inc. and FluoroPharma Medical, Inc., (FMPI). Mr. Sassine served in various positions at Fidelity Investments from 1999 to 2012, including, most recently as Portfolio Manager. Between 2004 and 2011, he managed the Fidelity Small Cap Stock Fund, the Fidelity International Small Cap Opportunities Fund and the Fidelity Advisor International Small Cap Opportunities Fund. Mr. Sassine joined Fidelity as a high yield research analyst, covering the Telecommunications, Satellite, Technology, Defense and Aerospace, and Restaurant Industries and in 2001, joined the international group as a research analyst covering small and mid-cap international stocks. Prior to joining Fidelity, he served as a vice president in the Acquisition Finance Group at Fleet National Bank. Mr. Sassine has been a member of the Henry B. Tippie College of Business, University of Iowa Board of Advisors since 2009 and served on the Board of Trustees at the Clarke Schools for Hearing and Speech between 2009 and 2014. Mr. Sassine earned a Bachelor of Arts degree at the University of Iowa in 1987 and an MBA from the Wharton School at the University of Pennsylvania in 1993.
Kevin SkolSenior Vice President, Business Development & Alliance Management Ji Young SukAssociate Director, Translational Biology Kiyoshi TachikawaSenior Research Fellow, Frontier Science Wendy TaylorDirector, Project Management Rachel Wilkie-GranthamScientist II, Frontier Science Ramon Diaz TrellesScientist II, Frontier Science Tran TrinhResearch Associate I, RNA Process Development Jerel VegaSenior Research Associate, Formulation Development Carina WimerResearch Associate II, Drug Discovery
Lishuang (Lily) XuResearch Associate II, Drug Discovery
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics is an industry leader in the application of RNA technologies for the treatment of disease and improved quality of life. The company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. Backed by a management team with extensive experience in the discovery and development of RNA medicines, Arcturus is on the forefront of research and development of RNA chemistry and delivery technologies.
November 7, 2018 Arcturus Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results read more
November 5, 2018 Arcturus Therapeutics Hosts Ribbon Cutting Ceremony for its Research and Development Facility read more
October 1, 2018 Arcturus Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update read more